Syncona

Syncona Update

May 2020

Syncona

Building the next generation of healthcare companies

Key Media Coverage

Fund Focus – Syncona Limited
The Sunday Times 31.05.2020

In the Sunday Times' Fund Focus column, Mark Atherton takes a look at Syncona, providing a brief overview of what the fund is, what it invests in and its performance. Within the article, John Moore of wealth manager Brewin Dolphin commented that, "Syncona . . . has the potential to be a FTSE 100 company if it is successful with some of the projects it has funded."

Achilles Therapeutics

Developing novel cancer immunotherapies targeting clonal neoantigens

Key Announcements

Formation of Scientific Advisory Board
13.05.2020

Announcement of Achilles SAB with three world renowned appointments; Dr Elizabeth M. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer. Dr Scott Antonia, currently serving as the chair of the thoracic oncology department at the H. Lee Moffitt Cancer Center and Research Institute. Dr Christopher A. Klebanoff, a leading cellular immunologist and medical oncologist at Memorial Sloan Kettering. The SAB will work closely with management and founders to advance pipeline.

Achilles Doses First Patient
29.05.2020

First patient dosed in a Phase I/II study of a clonal neoantigen T cell (cNeT) therapy in patients with recurrent or metastatic malignant melanoma demonstrating Achilles' capability to manufacture an entirely personalised T cell therapy. This is the first tumour-infiltrating lymphocyte (TIL) therapy to enter clinical trials where the TILs have been specifically selected to target clonal neoantigens – antigens which are believed to be present on all tumour cells.

Watch a video from the Achilles CEO and founders here.

Key Media Coverage

30 Rising Leaders In The Life Sciences
In Vivo 04.05.2020

In Vivo highlighted Iraj Ali, Chief Executive Officer of Achilles Therapeutics, as a rising leader in the life sciences. In a list of ‘Ones to Watch’ across the biopharma, medtech and health technology sectors, Lucie Ellis included Iraj as one of 30 innovators who represent the next wave of creativity in healthcare. Prior to becoming CEO of Achilles, Iraj was a managing partner at Syncona and was a board member for Nightstar Therapeutics, Blue Earth Diagnostics and Achilles itself.

Syncona

Autolus

Autolus

Developing next generation programmed T cell therapies for the treatment of cancer

Key Announcements

Autolus to Report First Quarter 2020 Financial Results and Host Conference Call on May 7
01.05.2020

Management held a conference call and webcast at 8:30 am ET/1:30 pm BST to discuss the company's financial results and provide a general business update.

Autolus Reports First Quarter 2020 Financial Results and Operational Progress
07.05.2020

Announcement of financial and operational results for the first quarter ended March 31, 2020.

Autolus to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program
14.05.2020

Announcement of an oral presentation related to AUTO3 program to be shown during the Annual Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program beginning May 29. Management will host a conference call and webcast on 1st June at 8:30 am EDT/1:30 pm BST to discuss the ASCO data.

Autolus to Present New Data at the Virtual 2020 AACR Annual Meeting
15.05.2020

Announcement of poster presentations related to AUTO5 in T cell lymphoma and AUTO6NG in small cell lung cancer, as well as an oral presentation related to AUTO7 in prostate cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on Jun 22 - 24, 2020. Management will host a conference call and webcast on 25th June at 8:30 am EDT/1:30 pm BST to discuss the AACR data.

Autolus to Present New Data on AUTO1 and AUTO3 at the 2020 EHA Annual Meeting
15.05.2020

Announcement of presentation related to AUTO1 and AUTO3 programs at the European Hematology Association EHA25 Virtual Congress on June 11 – 14, 2020. Management will host a conference call and webcast on 15th June at 8:30 am EDT/1:30 pm BST to discuss the EHA data.

Autolus Notice of Annual General Meeting (AGM) on Thursday, June 18, 2020
22.05.2020

Announcement notice of AGM to shareholders. The Notice states that the AGM is scheduled to be held at Autolus headquarters in White City at 1.00 pm BST (8.00 am EDT) on Thursday, June 18, 2020. Given the coronavirus pandemic, and in order to ensure that our AGM may proceed in compliance with the Stay at Home Measures, arrangements have been made for a quorum of two shareholders only to be present at our AGM this year.

Autolus Therapeutics to host Investor Conference Calls through June
26.05.2020

Management will host investor conference calls through June – with first call commencing on 1st June at 8.30 am EDT, 1.30 pm BST to discuss presentations related to its AUTO3 program.

Autolus Presents Additional Data AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program
29.05.2020

New data highlighting progress on AUTO3, the company's CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 study in relapsed/refractory diffuse large B cell lymphoma (DLBCL), presented during the Annual Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program beginning May 29.

"Data from the ALEXANDER trial of AUTO3, a CD19/CD22 dual-targeting CAR T product candidate in DLBCL have shown a complete response rate of 63% at the recommended Phase 2 dose range with an excellent safety profile," said Dr. Aravind Ramakrishnan, Medical Director, Bone Marrow Transplant and Cellular Therapy Program, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center. "We are encouraged by the current study results and have begun enrollment in an outpatient cohort to assess how this approach may benefit a greater population of DLBCL patients."

Freeline

Focused on developing curative gene therapies for chronic systemic diseases

Key Announcements

Freeline receives Orphan Drug Designation from the FDA for FLT190 for the treatment of Fabry Disease
04.05.2020

Announcement that the United States Food and Drug Administration has granted Orphan Drug Designation for FLT190 for the treatment of Fabry Disease. This comes soon after Freeline announced it had received Orphan Drug Designation for FLT190 from the European Commission, based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency.

Key Media Coverage

FDA Gives Fabry Gene Therapy, FLT190, Orphan Drug Status
Fabry Disease News | 12.05.2020

Fabry Disease News reported on Freeline's orphan drug designation for FLT190 as an investigational gene therapy for Fabry disease. "Fabry Disease has a wide spectrum of symptoms that can have a devastating impact on people's lives and we believe that FLT190 has the potential to be a functional cure that can halt progression of the disease and address many of these serious symptoms," Chris Hollowood said in the press release.

Key Videos

Gene therapy explained

Freeline have published an animation explaining what gene therapy is, how it has evolved over 50 years and the goal of providing a long-term cure for patients who receive treatment: watch here.

OMass

Harnessing native mass spectrometry to drug drive discovery in high definition

Key Announcements

OMass Announces Publication in Nature Methods
15.05.2020

Publication of a novel, highly enabling native mass spectrometry approach that marks a significant technical advance in the field. In collaboration with researchers from Oxford University, the Karolinska Institute and Thermo Fisher Scientific. The article was published in the 5th May 2020 print issue of Nature Method.

SwanBio

Developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of neurological diseases

Key Announcements

Appointment of Steven Zelenkofske, DO, as Chief Medical Officer
01.06.2020

Dr. Zelenkofske brings more than 20 years of experience to the SwanBio team, most recently serving as the CMO at Achillion Pharmaceuticals, a clinical stage company focused on complement inhibitors, and at UniQure, a clinical stage gene therapy company focused on genetic diseases. Dr. Zelenkofske has held leadership positions at Regado Biosciences, Astra-Zeneca, Sanofi-Aventis, Boston Scientific and Novartis. His work has spanned numerous therapeutic areas including neurology, immunology, hematology, cardiovascular, metabolic diseases, diabetes, and nephrology.